Mr. Wu Ting YukNon-executive Director, Chairman of the Board
Mr. Wu Ting Yuk has been appointed as an independent non-executive Director and the Chairman from August 8, 2018. Mr. Wu jointed the Hong Kong Hospital Authority in 1999 and was formerly its chairman from 2004 to 2013. Mr. Wu is currently also the principal advisor to the State Administration of Traditional Chinese Medicine of the People’s Republic of China, a member of the Chinese Medicine Reform and Development Advisory Committee. He was a member of the State Council’s Medical Reform Leadership Advisory Committee and an advisor to the Public Policy Advisory Committee of the National Health and Family Planning Commission. Other important public positions that Mr. Wu has served include member of the 12th and 13th Standing Committee of the Chinese People’s Political Consultative Conference National Committee, and a member of the Chief Executive’s Council of Advisers on Innovation and Strategic Development and the Task Force on Land Supply of the Hong Kong SAR, and has been award GBS and JP by the government of Hong Kong SAR. Mr. Wu also served as the chairman of the General Committee of the HK General Chamber of Commerce from 2010 to 2012, and is currently a member of its Council. Mr. Wu was a partner of Ernst & Young (“EY”) from 1985 to 2015, and served as chairman of the EY’s Far East Region from 2000 to 2005. He is also the chief advisor to MUFG Bank, Ltd., the chairman of The China Oxford Scholarship Fund, an honorary professor of the Faculty of Medicine of the Chinese University of Hong Kong and the Peking Union Medical College Hospital, and an honorary fellow of the Hong Kong College of Community Medicine. Mr. Wu also has directorships in certain listed companies of the Main Board of the Stock Exchange: he is an independent non-executive director of Power Assets Holdings Limited (Stock Code: 006), Guangdong Investment Limited (Stock Code: 270) and China Taiping Insurance Holdings Company Limited (Stock Code: 966), and an executive director of Sincere Watch (Hong Kong) Limited (Stock Code: 444). He was also an independent non-executive director of Agricultural Bank of China Limited (Stock Code: 1288) from 2009 to 2015. He was also a director of the Fidelity Funds from 2011 to 2014.
Mr. Kwong Kwok KongIndependent Non-Executive Director
Mr. Kwong Kwok Kong is an independent non-executive Director and also the chairman of the Audit Committee. He currently serves as the chief executive officer of Pok Oi Hospital, a well-known non-profit making hospital in Hong Kong. As the chief executive officer, Mr. Kwong has been providing corporate governance and management support to the board of directors for development, management and supervision of these units for the past 10 years. He initially joined Pok Oi Hospital as an internal audit manager in 2003. Before joining Pok Oi Hospital, Mr. Kwong served as the principal auditor of the Audit Commission of the Government of the Hong Kong Special Administrative Region. Mr. Kwong served in the Audit Commission of the Government of the Hong Kong Special Administrative Region since 1980. Mr. Kwong has been a member of the Hong Kong Institute of Certified Public Accountants since 1982.
Ms. Chiu Kam Hing KathyIndependent Non-Executive Director
Ms. Chiu Kam Hing Kathy is an independent non-executive Director and also the chairman of the Remuneration Committee and a member of the Audit Committee. Ms. Chiu is the chairlady of Prime Investments Group Limited and is currently an independent non-executive director of National Agricultural Holdings Limited (stock code: 01236), Sau San Tong Holdings Limited (stock code: 08200) and CPM Group Limited (stock code: 01932), whose shares are all listed on the Stock Exchange. Ms. Chiu was a senior vice president at the Republic National Bank of New York and was responsible for the management and investment of third party client’s funds. Ms. Chiu has been an associate and a fellow of the Institute of Canadian Bankers since July 1975 and August 1976 respectively. Ms. Chiu was appointed as a Justice of the Peace by the Hong Kong government in July 1992 and as a Cavaliere by the Italian Government in December 1998.
Mr. Lee Kar Chung FelixIndependent Non-Executive Director
Mr. Lee Kar Chung Felix is an independent non-executive Director and also a member of each of the Remuneration Committee and the Nomination Committee. Mr. Lee is currently a senior vice president of Chow Tai Fook Enterprises Limited, responsible for making investments in the healthcare sector in Asia and globally. He is also a director of Healthcare Ventures Holdings Limited, a wholly owned subsidiary of CTFE and substantial shareholder of UMP Healthcare Holdings. Mr. Lee is also an executive director of UMP Healthcare Holdings (Stock Code: 722), a leading corporate healthcare solutions provider in Hong Kong, where he is responsible for corporate development, international operations and merger and acquisitions. The Group, through Pinyu, owns 15% of UMP Healthcare Holdings as at the date of this annual report. Mr. Lee has over ten years of experience in law and finance. He wasan associate with the law firm Freshfields Bruckhaus Deringer before he left in February 2008 to join UBS AG, Hong Kong branch as an analyst in the investment banking department until January 2009. He then joined the investment banking department of Deutsche Bank AG, Hong Kong branch and last held the position of Director in the Corporate Advisory Group, where he worked from January 2009 to August 2014.
Mr. Lee obtained his bachelor degree in Laws from the London School of Economics and Political Sciences and his Postgraduate Certificate in Laws from The University of Hong Kong in July 2003 and June 2004, respectively. He is a solicitor of the High Court of Hong Kong since September 2007 and a solicitor (non-practising) in the Senior Courts of England and Wales since February 2013.
Mr. Wang YanNon-executive Director
Mr. Wang Yan has been appointed as a non-executive Director from November 25, 2016 and a member of the Audit Committee from December 28, 2016. He joined China Resources National Corporation in July 1994. From February 2016, Mr. Wang has been appointed as the chief internal auditor of Internal Audit & Supervision Department of CR Holdings. Since August 2014, Mr. Wang has been appointed as the non-executive director of China Resources Cement Holdings Limited (stock code: 1313), China Resources Gas Group Limited (stock code: 1193), China Resources Land Limited (stock code: 1109) and China Resources Power Holdings Company Limited (stock code: 836). From August 2014 to April 2016, Mr. Wang was a non-executive director of China Resources Beer (Holdings) Company Limited (stock code: 291). He was a deputy chief internal auditor of Internal Audit & Supervision Department of CR Holdings between April 2012 and February 2016. Mr. Wang was a deputy general manager of China Resources Gas (Holdings) Limited from September 2007 to April 2012. Mr. Wang was appointed as a director of China Resources Gas Limited in November 2005. He worked for China Resources Petrochems (Group) Company Limited (currently known as Sinopec (Hong Kong) Petroleum Holding Company Limited) from 2000 to 2007. Mr. Wang obtained a Bachelor's degree in economics from the Finance and Accounting Department, Capital University of Economics and Business and obtained a Master's degree in Business Administration from the University of South Australia. Mr. Wang is a qualified PRC Certified Accountant.
Mr. Song QingExecutive Director,Vice Chairman
Mr. Song Qing has been appointed as an executive Director and the Vice Chairman from August 7, 2018. Mr. Song holds a bachelor’s degree in Chinese medicine from Anhui University of Traditional Chinese Medicine in Hefei, the PRC, and obtained his chief pharmacist title from the general logistics department of the People’s Liberation Army in April 1996. Mr. Song was the director of China Resources Pharmaceutical Group Limited (which is listed on the Main Board of the Stock Exchange; Stock Code: 3320) from May 2016 to August 2018, and also its president from June 2017 to August 2018. Mr. Song is the director of China Resources Sanjiu Medical & Pharmaceutical Co Ltd (which is listed on Shenzhen Stock Exchange; Stock Code: 000999). He served as an inspection pharmacist of quality inspection department, a pharmacist in charge and the director of production department, the director of the enterprise management department and an assistant to president of Shenzhen South Pharmaceutical Factory, the general manager and chairman of Shanxi Sanjiu Tongda Pharmaceutical Company Limited (山西三九同达药业有限公司) (currently known as Shanxi Tongda Pharmaceutical Company Limited (山西同达药业有限公司)). Mr. Song served as an assistant general manager, the director of technology center, the director of medical & pharmaceutical department of Sanjiu Enterprise. Mr. Song is currently the chairman of China Resources Healthcare Group Limited and also takes the role as the Company’s vice chairman in order to lead the healthcare segment of China Resources.
Mr. Cheng LibingExecutive Director, Chief Executive Officer of the Group
Mr. Cheng Libing is an executive Director and the chief executive officer of the Group. Mr. Cheng joined the Group in September 2010 and is primarily responsible for daily operations of the Group. He also served as an executive Director and the vice Chairman of the Group from February 2016 to August 2018. Mr. Cheng served as the deputy general manager of Beijing Huaren Intech Hospital Management Consulting Co., Ltd. (北京华仁英智医院管理咨询有限公司) from 2006 to 2008 and the deputy general manager of Beijing Huaren Intech Hospital Management Consulting Co., Ltd., Beijing Intech Eye Hospital Co., Ltd. (北京英智眼科医院有限公司) and Intech Medical Chain (英智医疗连锁机构) from 2008 to 2010. From 1999 to 2002, Mr. Cheng has served various positions at Beijing Kangchen Pharmaceutical Co., Ltd. (北京康辰医药发展有限公司), including general manager assistant. Mr. Cheng also worked as a resident doctor at Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine (北京中医药大学附属东直门医院) from 1988 to 1998. Mr. Cheng received a Bachelor's degree in Traditional Chinese Medicine from Beijing University of Chinese Medicine (北京中医药大学) in Beijing in July 1988.
Ms. Ren YuanExecutive Director, Chief Financial Officer
Ms. Ren Yuan joined the Group and was appointed as executive director and CFO in October 2017. Ms. Ren worked as the deputy manager of the finance department of China Resources Microelectronics (Holdings) Limited from June 2002 to June 2006. From February 2004 to February 2010, Ms. Ren served as the finance director of Wuxi CR Micro-Assemb Tech., Ltd.. Prior to joining the Group, Ms. Ren worked as the consultancy director and deputy general director of the information management department of China Resources (Holdings) Co., Ltd. since February 2010. Ms. Ren obtained her master’s degree in accounting from Chinese University of Hong Kong in December 2007. Ms. Ren obtained the qualifications of China Certified Public Accountant and China Certified Public Valuer in December 1998, and September 1999, respectively.
Ms. Fu YanjunExecutive Director, Deputy General Manager
Ms. Fu Yanjun joined the group in December of 2014 and was appointed as deputy general manager and executive director in November 2016 and in October 2017 respectively. Ms. Fu also previously served as the managing director of strategic investment department of the Company, the chairman of the board and the general manager of Beijing Wanrong Yikang Pharmaceutical Company Limited and Beijing Phoenix Jiayi Medical Equipment Company Limited, which are wholly-owned subsidiaries of the Company, and the executive chairman and the chairman of the youth committee of the Group. Ms. Fu also worked for Ernst & Young Hua Ming and Deloitte Touche Tohmatsu CPA Ltd. from September 2002 to December 2014. Ms. Fu obtained a bachelor's degree in accounting from Renmin University of China in July 2002 and obtained the qualification of China Certified Public Accountant in May 2008.